Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp30151_8k.htm |
Exhibit 99.01
|
Press Release
|
 |
|
www.shire.com
|
Results of the Annual General Meeting held on April 24, 2012
Dublin, Ireland – April 24, 2012 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company (the “Company”) announces that at its Annual General Meeting today, all resolutions contained in the notice of meeting were duly passed and the results of the poll are as follows:
|
For*
|
%
|
Against
|
%
|
Withheld**
|
Total votes validly cast
|
% of relevant shares in issue†
|
|||
|
1.
|
To receive the Company’s accounts together with the reports of the Directors and Auditor
|
418,002,081
|
99.53
|
1,976,774
|
0.47
|
148,326
|
419,978,855
|
74.66
|
|
|
2.
|
To approve the Directors’ remuneration report
|
411,583,191
|
98.39
|
6,730,515
|
1.61
|
1,813,475
|
418,313,706
|
74.36
|
|
|
3.
|
To re-elect William Burns as a Director of the Company
|
419,093,911
|
99.80
|
850,198
|
0.20
|
183,072
|
419,944,109
|
74.65
|
|
|
4.
|
To re-elect Matthew Emmens as a Director of the Company
|
398,450,620
|
95.32
|
19,569,781
|
4.68
|
2,106,780
|
418,020,401
|
74.31
|
|
|
5.
|
To re-elect Dr. David Ginsburg as a Director of the Company
|
419,160,380
|
99.81
|
783,870
|
0.19
|
182,931
|
419,944,250
|
74.65
|
|
|
6.
|
To re-elect Graham Hetherington as a Director of the Company
|
419,789,314
|
99.96
|
153,128
|
0.04
|
184,739
|
419,942,442
|
74.65
|
|
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
|
7.
|
To re-elect David Kappler as a Director of the Company
|
419,860,547
|
99.98
|
80,764
|
0.02
|
185,870
|
419,941,311
|
74.65
|
|
|
8.
|
To re-elect Anne Minto as a Director of the Company
|
419,851,750
|
99.98
|
91,564
|
0.02
|
183,867
|
419,943,314
|
74.65
|
|
|
9.
|
To re-elect Angus Russell as a Director of the Company
|
419,854,943
|
99.98
|
84,052
|
0.02
|
188,186
|
419,938,995
|
74.65
|
|
|
10.
|
To re-elect David Stout as a Director of the Company
|
419,139,038
|
99.81
|
804,195
|
0.19
|
183,948
|
419,943,233
|
74.65
|
|
|
11.
|
To elect Susan Kilsby as a Director of the Company
|
419,858,255
|
99.98
|
83,492
|
0.02
|
185,434
|
419,941,747
|
74.65
|
|
|
12.
|
To re-appoint Deloitte LLP as Auditor of the Company
|
419,580,038
|
99.91
|
382,738
|
0.09
|
164,405
|
419,962,776
|
74.66
|
|
|
13.
|
To authorize the Audit, Compliance & Risk Committee to determine the remuneration of the Auditor
|
419,952,105
|
99.99
|
35,533
|
0.01
|
139,543
|
419,987,638
|
74.66
|
|
|
14.
|
To authorize the allotment of shares
|
378,250,630
|
91.29
|
36,074,487
|
8.71
|
5,802,064
|
414,325,117
|
73.65
|
|
|
15.
|
To authorize the disapplication of pre-emption rights
|
411,936,691
|
98.41
|
6,655,573
|
1.59
|
1,534,917
|
418,592,264
|
74.41
|
|
|
16.
|
To authorize market purchases
|
419,037,905
|
99.80
|
840,219
|
0.20
|
249,057
|
419,878,124
|
74.64
|
|
|
17.
|
To approve the reduced notice period for general meetings
|
367,519,055
|
87.51
|
52,460,162
|
12.49
|
147,964
|
419,979,217
|
74.66
|
* These figures include discretionary votes
** A vote “withheld” is not a vote in law and is not counted in the calculation of the proportion of votes validly cast
†As at the record date, April 22, 2012, there were 562,532,330 ordinary shares in issue. Shareholders are entitled to one vote per share.
In accordance with Listing Rule 9.6.2 copies of the relevant resolution passed at the meeting have been submitted to the National Storage Mechanism and will be available for viewing shortly at: www.hemscott/nsm.do.
For further information please contact:
|
Investor Relations
|
||
|
Eric Rojas
|
erojas@shire.com
|
+1 781 482 0999
|
|
Sarah Elton-Farr
|
seltonfarr@shire.com
|
+44 1256 894157
|
|
Media
|
||
|
Jessica Mann (Corporate)
|
jmann@shire.com
|
+44 1256 894 280
|
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.